Stockscreener 앱 받기
6.28
7.17%
0.42
시간 외 거래:
6.28
전일 마감가:
$5.86
열려 있는:
$5.84
하루 거래량:
635.58K
Relative Volume:
2.46
시가총액:
$133.10M
수익:
$73.62M
순이익/손실:
$-138.24M
주가수익비율:
-0.9949
EPS:
-6.3125
순현금흐름:
$-99.19M
1주 성능:
+4.15%
1개월 성능:
-30.84%
6개월 성능:
-45.06%
1년 성능:
-26.29%
1일 변동 폭
$5.72
$6.31
1주일 범위
$5.70
$6.56
52주 변동 폭
$5.70
$17.80
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
500 ARSENAL STREET, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
6.28 | 133.10M | 73.62M | -138.24M | -99.19M | -6.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress buoys stock outlook - Investing.com
(ENTA) Technical Data - Stock Traders Daily
Enanta stock touches 52-week low at $6.36 amid market challenges - Investing.com Canada
FY2025 Earnings Estimate for ENTA Issued By Leerink Partnrs - Defense World
Leerink Partnrs Has Positive Outlook of ENTA FY2025 Earnings - MarketBeat
Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 By Investing.com - Investing.com Canada
Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock By Investing.com - Investing.com Canada
Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 - Investing.com
Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock - Investing.com
Point72 Asset Management L.P. Buys New Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
Enanta Pharmaceuticals chief scientific officer sells shares worth $20,883 By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock By Investing.com - Investing.com Canada
Enanta Pharmaceuticals CEO sells $41,444 in stock By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals CFO sells shares worth $20,883 - Investing.com
Enanta Pharmaceuticals CEO sells $41,444 in stock - Investing.com
Enanta Pharmaceuticals chief business officer sells $18,400 in stock By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals CFO sells shares worth $20,883 By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals chief business officer sells $18,400 in stock - Investing.com
Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock - Investing.com
Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial - Yahoo Finance
Enanta logs phase II RSV win with zelicapavir - BioWorld Online
Enanta Pharmaceuticals Sees Positive Topline Results for RSV Drug Trials - MarketWatch
LogoEnanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) - BioSpace
Enanta's RSV Drug Zelicapavir Shows Strong Antiviral Effects in Landmark Pediatric Trial - StockTitan
Enanta Pharma to Unveil Breakthrough RSV Pediatric Trial ResultsKey Phase 2 Data Coming - StockTitan
Enanta stock touches 52-week low at $7.99 amid market challenges - Investing.com Nigeria
Erste Asset Management GmbH Purchases New Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
Enanta Pharmaceuticals (FRA:9EP) 3-Year FCF Growth Rate : -9.20% (As of Sep. 2024) - GuruFocus.com
Caligan Partners LP Cuts Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $19.50 - MarketBeat
Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 - Marketscreener.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP Securities - Defense World
Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report - Simply Wall St
Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility - Yahoo Finance
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline and cash position fuel stock outlook - Investing.com
ENTA (Enanta Pharmaceuticals) Accounts Receivable : $6.65 Mil (As of Sep. 2024) - GuruFocus.com
Robert W. Baird Has Lowered Expectations for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price - Defense World
Enanta Pharmaceuticals Inc. (ENTA) reports earnings - Quartz
Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet - Simply Wall St
Enanta Pharmaceuticals (STU:9EP) Cash Flow from Operations : €-83.19 Mil (TTM As of Jun. 2024) - GuruFocus.com
Enanta stock touches 52-week low at $8.45 amid market challenges - Investing.com Canada
4 Analysts Assess Enanta Pharma: What You Need To Know - Benzinga
Leerink raises Enanta price target to $12 from $10, keeps rating - Investing.com UK
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):